

## Olomoucine

Cat. #: O-300

Current Lot #: O300OL0101, O300OL011


Source description: Synthetic.

M.W.: 298.35 daltons.

Purity: >99%.

Effective concentration: 20-200  $\mu$ M.

Structure:



Chemical name: 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine.

Molecular formula:  $C_{15}H_{18}N_6O$ .

CAS No.: 101622-51-9.

**Activity:** Olomoucine selectively inhibits cdc2/cyclin B ( $IC_{50} = 7 \mu$ M), cdk2/cyclin A ( $IC_{50} = 7 \mu$ M), cdk2/cyclin E ( $IC_{50} = 7 \mu$ M), cdk/p35 kinase ( $IC_{50} = 3 \mu$ M) and ERK1/MAP kinase at higher concentrations ( $IC_{50} = 25 \mu$ M)<sup>1</sup>. It also prevents NGF-mediated survival of neuronal cells<sup>2</sup>.

References:

1. Veseley, J. *et al.* (1994) *Eur. J. Biochem.* **224**, 771.
2. Monaco, E.A. *et al.* (2004) *Biochem. Pharmacol.* **67**, 1947.


Sizes: 1 mg, 5 x 1 mg, 5 mg or 10 x 0.1 mg lyophilized powder.

**Storage before reconstitution:** Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at  $-20^{\circ}C$ .

**Reconstitution:** DMSO. Centrifuge all product preparations before use (10000 x g 5 min).

**Storage and stability after reconstitution:** Up to two weeks at  $4^{\circ}C$  or six months at  $-20^{\circ}C$ .

**Bioassay:** Olomoucine prevents NGF-mediated survival of PC-12 cells.



Cells were grown in the absence of serum. The cells were not protected (dotted line) or protected (continuous line) from apoptosis with 100 ng/ml **mNGF 2.5S (Grade I) (#N-240)** and treated with different concentrations of **Olomoucine (#O-300)**. Cell survival was measured after 4 days using the XTT method, calculated as a relative percentage of the control without Olomoucine and plotted against Olomoucine concentrations.

For research purposes only, not for human use.  
Last Update: May, 2010.